Aimei Health Technology Co., Ltd SEC Filings

afjku NASDAQ

Welcome to our dedicated page for Aimei Health Technology Co. SEC filings (Ticker: afjku), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Struggling to spot the next health-tech deal hidden in Aimei Health Technology Co., Ltd’s dense SPAC disclosures? Each 200-page prospectus, 10-K, or 8-K is packed with trust-account math, sponsor warrants, and redemption clauses that can affect your return long before a merger closes.

Stock Titan’s AI turns those complexities into clarity. Our platform delivers real-time alerts the moment an Aimei Health Technology Co., Ltd 8-K material events explained filing appears on EDGAR and produces plain-English summaries so you can see, in seconds, whether a definitive agreement or extension vote is on the table. Need ownership details? The dashboard highlights Aimei Health Technology Co., Ltd Form 4 insider transactions real-time, letting you monitor sponsor purchases, redemptions, or warrant exercises without scrolling through multiple exhibits.

Key filings we cover and decode:

10-K annual report – cash held in trust, deadline milestones, and sponsor economics, all in an Aimei Health Technology Co., Ltd annual report 10-K simplified format.
10-Q quarterly update – trust interest income and expense trends inside the Aimei Health Technology Co., Ltd quarterly earnings report 10-Q filing.
8-K – every material event, from LOIs to business-combination announcements, with Aimei Health Technology Co., Ltd 8-K material events explained.
DEF 14A proxy statement – see Aimei Health Technology Co., Ltd proxy statement executive compensation details and vote deadlines.
Form 4 – track Aimei Health Technology Co., Ltd insider trading Form 4 transactions and other Aimei Health Technology Co., Ltd executive stock transactions Form 4.

Whether you’re comparing warrant terms, timing a redemption, or just understanding Aimei Health Technology Co., Ltd SEC documents with AI, our concise notes, key-figure extracts, and trend charts provide the Aimei Health Technology Co., Ltd SEC filings explained simply experience investors rely on. Save hours, avoid surprises, and focus on what moves SPAC valuations.

07/07/2025 04:05 PM

Filing

[8-K] Aimei Health Technology Co., Ltd Unit Reports Material Event

Rhea-AI Summary

Karpus Management, Inc. filed Amendment No. 2 to Schedule 13G for Eureka Acquisition Corp (EURKU) covering the event date 30 June 2025.

The registered investment adviser now reports beneficial ownership of 327,400 common shares, representing 4.28 % of the outstanding class. Karpus holds sole voting and dispositive power over the entire position and no shared power with other parties. Because the stake has fallen below the 5 % threshold, Karpus is no longer deemed a 5 % beneficial owner under Section 13(d) of the Exchange Act but remains subject to Rule 13d-1(b) reporting requirements.

The shares are held in discretionary advisory accounts managed by Karpus, which operates independently of its parent, City of London Investment Group plc, through established informational barriers. The filing affirms that the securities were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.

Implications for investors: the reduction slightly increases EURKU’s public float and removes Karpus from the list of significant 5 % holders, potentially diminishing expectations of activist involvement. Nonetheless, a 4.28 % position remains a meaningful minority interest that could provide ongoing institutional oversight.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Aimei Health Technology Co. (afjku)?

The current stock price of Aimei Health Technology Co. (afjku) is $11.25 as of July 1, 2025.

What is a blank check company?

A blank check company is a firm set up to raise capital through an initial public offering with the aim of acquiring or merging with an existing business. It is commonly structured as a special purpose acquisition company or SPAC.

How does Aimei Health Technology generate revenue?

As a blank check company, Aimei Health Technology does not generate revenue through traditional operations. Its primary focus is on using raised capital to execute strategic acquisitions in the health technology sector.

What strategic opportunities does Aimei Health Technology pursue?

The company seeks to identify and acquire businesses that align with its focus in the health technology and life sciences domains. Its strategy is built on leveraging market expertise and transaction planning to tap into emerging industry trends.

How is the transaction process structured at Aimei Health Technology?

Aimei Health Technology follows a structured transaction approach, which includes comprehensive due diligence and adherence to regulatory guidelines. The process is detailed through clearly explained transaction overviews and key terms.

What distinguishes Aimei Health Technology from other companies in the sector?

Unlike traditional operating companies, Aimei Health Technology is dedicated solely to identifying meaningful acquisitions through its blank check structure. This specialized focus allows the company to offer a unique investment platform in the health technology space.

How does the company ensure compliance and transparency?

The company adopts a rigorous approach in its transaction procedures, emphasizing thorough due diligence and clear disclosure of transaction terms. This structure supports high levels of compliance and transparency in all its operations.

What role does industry analysis play in Aimei Health Technology's strategy?

Industry analysis is central to the company’s strategy, ensuring that every potential acquisition aligns with current health technology trends and market dynamics. It helps the company identify viable targets and execute well-informed transactions.